First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial

European Journal of Cancer

Volumn 50, Issue 13, 2014, Pages 2219-2230

  Yang, James Chih Hsin ^a   Kang, Jin Hyoung ^b   Mok, Tony ^c   Ahn, Myung Ju ^d   Srimuninnimit, Vichien ^e   Lin, Chia Chi ^a   Kim, Dong Wan ^f   Tsai, Chun Ming ^g   Barraclough, Helen ^h   Altug, Sedat ^h   Orlando, Mauro ^h   Park, Keunchil ^d  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b The Catholic University of Korea   (South Korea)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e MAHIDOL UNIVERSITY   (Thailand)

^f Seoul National University Hospital   (South Korea)

^g TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^h ELI LILLY AND COMPANY   (United States)

Author keywords

Cisplatin; East Asian patients; Gefitinib; Non squamous non small cell lung cancer; Pemetrexed

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GEFITINIB; GLUTAMIC ACID DERIVATIVE; GUANINE; PEMETREXED; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENETICS; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES; YOUNG ADULT;

EID: 84905105613     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.05.011     Document Type: Article

References (29)

1. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2893 2917
2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer. Version 2. http://www.nccn.org/ professionals/physician-gls/pdf/nscl.pdf; 2013 [accessed 22.08.13].
3. C.G. Azzoli, S. Temin, and T. Aliff et al. Focused update of 2009 American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer J Clin Oncol 29 2011 3825 3831
4. G. D'Addario, M. Früh, M. Reck, P. Baumann, W. Klepetko, and E. Felip Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 21 Suppl. 5 2010 v116 v119
5. M. Li, Q. Zhang, and P. Fu et al. Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials PLoS One 7 2012 e37229
6. J.C. Soria, A. Mauguen, and M. Reck et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer Ann Oncol 24 2013 20 30
7. K. Park, and K. Goto A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer Curr Med Res Opin 22 2006 561 573
8. F.A. Shepherd, J. Rodrigues Pereira, and T. Ciuleanu et al. Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
9. N. Thatcher, A. Chang, and P. Parikh et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 2005 1527 1537
10. T. Kosaka, Y. Yatabe, H. Endoh, H. Kuwano, T. Takahashi, and T. Mitsudomi Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications Cancer Res 64 2004 8919 8923
11. H. Shigematsu, L. Lin, and T. Takahashi et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst 97 2005 339 346
12. T.J. Lynch, D.W. Bell, and R. Sordella et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
13. J.G. Paez, P.A. Jänne, and J.C. Lee et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
14. W. Pao, V. Miller, and M. Zakowski et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101 2004 13306 13311
15. T.S. Mok, Y.L. Wu, and S. Thongprasert et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
16. Eli Lilly and Company. ALIMTA (pemetrexed) US prescribing information. Indianapolis: Eli Lilly and Company. http://pi.lilly.com/us/alimta-pi.pdf; 2013 [accessed 09.09.13].
17. European Medicines Agency. Alimta. 11/23/2012 update. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 000564/human-med-000638.jsp&mid=WC0b01ac058001d124 [accessed 09.09.13].
18. G.V. Scagliotti, P. Parikh, and J. von Pawel et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
19. L. Paz-Ares, F. de Marinis, and M. Dediu et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial Lancet Oncol 13 2012 247 255
20. L. Paz-Ares, F. De Marinis, and M. Dediu et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer J Clin Oncol 31 2013 2895 2902
21. T. Ciuleanu, T. Brodowicz, and C. Zielinski et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Lancet 374 2009 1432 1440
22. C.H. Yang, L. Simms, K. Park, J.S. Lee, G. Scagliotti, and M. Orlando Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial J Thorac Oncol 5 2010 688 695
23. M.J. Ahn, J.C. Yang, and J. Liang et al. Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer Lung cancer 77 2012 346 352
24. I.D. Fleming, J.S. Cooper, and D.E. Henson et al. AJCC cancer staging manual 5th ed. 1997 Lippincott-Raven Philadelphia
25. C.F. Mountain Revisions in the international system for staging lung cancer Chest 111 1997 1710 1717
26. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
27. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE), 8/2006 update. http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3.pdf [09.09.13].
28. C. Gridelli, F. Ciardiello, and C. Gallo et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial J Clin Oncol 30 2012 3002 3011
29. T.S. Mok, Y.L. Wu, and C.J. Yu et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer J Clin Oncol 27 2009 5080 5087